Developing a structural equation model for the life cycle of generic pharmaceutical products

Atefeh Mousavi, Marjan Monadizadeh, M. Mohammadzadeh
{"title":"Developing a structural equation model for the life cycle of generic pharmaceutical products","authors":"Atefeh Mousavi, Marjan Monadizadeh, M. Mohammadzadeh","doi":"10.1177/17411343221076744","DOIUrl":null,"url":null,"abstract":"Objective Product life cycle (PLC) refers to the time ranging from when a product is introduced into the market until it is taken off the shelves. Product life cycle management can guarantee product survival and prevent it from declining. The purpose of this study is to explore factors influencing the life cycle of generic pharmaceutical product and their effect sizes to shed light on better approaches for the life cycle management of such products. Method To this end, a standard questionnaire containing six dimensions and 47 items was used to collect data from 302 industrial pharmacists. The research hypotheses were tested using structural equation modeling to quantify the relationship between each dimension and its associated factors with the PLC. Key finding The results indicated that government interventions (Standard estimate (SE) = 0.63) and technology advancement (SE = 0.60) as environmental factors, quality (SE = 0.60) and price (SE = 0.62) satisfaction, patient adherence (SE = 0.68), physicians' awareness (SE = 0.64), market saturation (SE = 0.60); and demand rate (SE = 0.62) as demand factors, brand power (SE = 0.92); and availability of imported competitors (SE = 0.59) as competition factors, drug safety (SE = 0.63), product appearance (SE = 0.57); and ease of administration (SE = 0.61) as product-related factors, manufacturer reputation (SE = 0.63); and production continuity (SE = 0.64) as producer-related factors, and distributors number (SE = 0.54); and on-time delivery and availability of products (SE = 0.69) as distributor-related factors at 5% significance levels had the most effect on generic pharmaceutical PLC in Iran. Conclusion For the first time, this study offers a structural equation modeling framework for better managing the PLC of generic pharmaceutical products to help the company’s performance and survival.","PeriodicalId":15914,"journal":{"name":"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector","volume":"11 1","pages":"176 - 186"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17411343221076744","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective Product life cycle (PLC) refers to the time ranging from when a product is introduced into the market until it is taken off the shelves. Product life cycle management can guarantee product survival and prevent it from declining. The purpose of this study is to explore factors influencing the life cycle of generic pharmaceutical product and their effect sizes to shed light on better approaches for the life cycle management of such products. Method To this end, a standard questionnaire containing six dimensions and 47 items was used to collect data from 302 industrial pharmacists. The research hypotheses were tested using structural equation modeling to quantify the relationship between each dimension and its associated factors with the PLC. Key finding The results indicated that government interventions (Standard estimate (SE) = 0.63) and technology advancement (SE = 0.60) as environmental factors, quality (SE = 0.60) and price (SE = 0.62) satisfaction, patient adherence (SE = 0.68), physicians' awareness (SE = 0.64), market saturation (SE = 0.60); and demand rate (SE = 0.62) as demand factors, brand power (SE = 0.92); and availability of imported competitors (SE = 0.59) as competition factors, drug safety (SE = 0.63), product appearance (SE = 0.57); and ease of administration (SE = 0.61) as product-related factors, manufacturer reputation (SE = 0.63); and production continuity (SE = 0.64) as producer-related factors, and distributors number (SE = 0.54); and on-time delivery and availability of products (SE = 0.69) as distributor-related factors at 5% significance levels had the most effect on generic pharmaceutical PLC in Iran. Conclusion For the first time, this study offers a structural equation modeling framework for better managing the PLC of generic pharmaceutical products to help the company’s performance and survival.
建立非专利药品生命周期结构方程模型
产品生命周期(PLC)是指从产品进入市场到下架的时间范围。产品生命周期管理可以保证产品的生存,防止产品的衰亡。本研究的目的是探讨影响仿制药生命周期的因素及其效应量,为仿制药生命周期管理提供更好的途径。方法采用6个维度47个项目的标准问卷对302名工业药师进行调查。使用结构方程模型对研究假设进行了检验,以量化每个维度及其相关因素与PLC之间的关系。结果表明:政府干预(标准估计(SE) = 0.63)和技术进步(SE = 0.60)为环境因素,质量(SE = 0.60)和价格(SE = 0.62)满意度、患者依从性(SE = 0.68)、医生认知度(SE = 0.64)、市场饱和度(SE = 0.60)为环境因素;以需求率(SE = 0.62)为需求因素,品牌力(SE = 0.92);竞争因素为进口竞争者的可获得性(SE = 0.59)、药品安全性(SE = 0.63)、产品外观(SE = 0.57);与产品相关的因素有:管理方便度(SE = 0.61)、制造商声誉(SE = 0.63);生产者相关因素为生产连续性(SE = 0.64),经销商数量(SE = 0.54);和准时交货和产品可得性(SE = 0.69)作为分销商相关因素在5%显著水平上对伊朗仿制药PLC影响最大。结论本研究首次为更好地管理仿制药PLC提供了结构方程建模框架,以帮助仿制药企业提高绩效和生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信